Back to search

Belgium· BE-AMP-SAM528462-00

Segluromet 2.5 mg - 850 mg

A metformin and ertugliflozin product containing ertugliflozin l-pyroglutamic acid, registered in Belgium by Merck Sharp & Dohme. The same ATC class is registered in 8 of our 19 countries.

ATC A10BD23

Checked against FAMHP / AFMPS (Belgium) on

Informational only — not a medical device.

SOURCE REGISTER · BEFAMHP / AFMPS (Belgium)normalisedSegluromet 2.5 mg - 850 mgATCA10BD23REGISTER NO.BE-AMP-SAM528462-00PACKS LISTED0CHECKEDSeptember 26, 2026

Where it is registered

Metformin and ertugliflozin is registered in 8 of 19 countries.

Countries holding a registration under ATC A10BD23 (metformin and ertugliflozin), each read from that country’s own register.

  • This record: Belgium, from FAMHP / AFMPS (Belgium)
  • 5 of them publish a price we can compare per daily dose

Metformin and ertugliflozin · ATC A10BD23

8 / 19 countries

  • Belgiumprice
  • Czechiaprice
  • Denmark
  • Finlandprice
  • Icelandprice
  • Ireland
  • Netherlands
  • Polandprice
Blue: a registration under this ATC code. The ringed marker is this record’s country. Markets marked price publish a price we can compare per daily dose.

The record

At a glance

FAMHP / AFMPS (Belgium)
Active substance
Ertugliflozin L-Pyroglutamic Acid
Manufacturer
Merck Sharp & Dohme
Country
Belgium (BE)
ATC code
A10BD23
ATC class
Metformin and ertugliflozin
Reimbursed
Not published by this register
Source register
FAMHP / AFMPS (Belgium)
Last checked
September 26, 2026

Packs & prices · 0

No packs listed by the register for this record.

Regulatory notes

No shortage, Orange Book or US label notes for this record.

Same medicine, other countries

Metformin and ertugliflozin in 3 other countries

What each register calls a product with the same active substance — salts and hydrates count as the same.

All metformin and ertugliflozin products

Sourced from a public register and reproduced with attribution. Drug Database is not affiliated with, endorsed by, or a partner of FAMHP / AFMPS (Belgium). This is an informational data service and not a medical device — verify against the official source of record before any clinical decision.

For developers

The same record over the API, and the raw payload
GET /v1/drugs/b94cd223-1ef1-48a0-bbf4-b5315e48a92b
GET /v1/drugs/b94cd223-1ef1-48a0-bbf4-b5315e48a92b?format=fhir

Every response carries last_synced_at, so freshness is a field rather than a promise. Below is exactly what the ingestion wrote, before any presentation — the same JSON the API returns under payload.

{
  "form": "Film-coated tablet",
  "source": "afmps",
  "status": "AUTHORIZED",
  "name_en": "Segluromet 2.5 mg - 850 mg",
  "name_fr": "Segluromet 2.5 mg - 850 mg",
  "name_nl": "Segluromet 2.5 mg - 850 mg",
  "amp_code": "SAM528462-00",
  "strengths": [
    "2.5000",
    "2.5000",
    "850.0000",
    "850.0000",
    "2.5000"
  ],
  "pack_count": 8,
  "substances": [
    "Ertugliflozin L-Pyroglutamic Acid",
    "Ertugliflozin",
    "Metformin Hydrochloride",
    "Sodium Laurilsulfate"
  ],
  "medicine_type": "ALLOPATHIC",
  "atc_description": "Metformin and Ertugliflozin",
  "authorisation_numbers": [
    "EU/1/18/1265/001",
    "EU/1/18/1265/003",
    "EU/1/18/1265/002",
    "EU/1/18/1265/005",
    "EU/1/18/1265/004",
    "EU/1/18/1265/007",
    "EU/1/18/1265/006",
    "EU/1/18/1265/029"
  ]
}

See everything about metformin and ertugliflozin.

This page is the registration. A free account adds the label text as the regulator wrote it, what it costs per daily dose across the markets that publish a price, a feed of what changes in the registers, and an assistant that answers with its sources. Interaction severity is free; mechanism and management are on the Growth plan. No card, nothing to install.